A range of experts provided opinions on the FDA’s approval of a blood test for colorectal cancer (CRC) screening. While some view it as a convenient option for those reluctant to undergo traditional methods, concerns persist regarding its limited ability to detect early-stage cancers and advanced precancerous lesions. Experts highlight the need for follow-up colonoscopies after a positive test and worry about potential disparities in access due to its high cost. Ultimately, the test is seen as supplementary, not a replacement for established screening methods.
Keep Reading
Add A Comment